| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2107533 | Cancer Cell | 2011 | 4 Pages |
Abstract
Despite the promise of the new generation of molecularly targeted drugs, intrinsic and acquired resistance is proving to be as problematic as with cytotoxic drugs. Two recent papers have identified novel ways by which non-small cell lung cancers can exhibit resistance to EGFR inhibitors and suggest new therapeutic workarounds.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Paul Workman, Paul A. Clarke,